Physician profile
Robin Sherchan
NPI 1740844208
$2,014.77
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,367 · 2024: $476 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.28 | 2023 | Avycaz, Teflaro, Mavyret |
| Gilead Sciences, INC. | $459.42 | 2023-2024 | Epclusa, Veklury |
| La Jolla Pharmaceutical Company | $232.74 | 2023 | Xerava, Xacduro |
| Melinta Therapeutics, LLC | $231.02 | 2024 | Vabomere, Kimyrsa |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Viiv Healthcare Company | $96.90 | 2024 | Apretude |
| Astellas Pharma US INC | $86.13 | 2023 | Cresemba |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.35 | 2024-2025 | Lifevest |
| Pfizer INC. | $42.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.34 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $34.61 | 2025 | Eliquis |
| Merck Sharp & Dohme LLC | $19.10 | 2025 | Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Sherchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.